Analytical Data
-
Gene name
NRG1-beta 2
- Application
-
Alternative Names
Pro-NRG1; Neuregulin-1; ARIA; HRG; NRG1
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q02297-7
-
Expression Region
S20-K238
-
Protein Length
Extracellular Domain
-
Molecular Weight
35-45 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NRG1 (neuregulin-1) is a crucial signaling molecule involved in various biological processes, including neural development, cardiac function, and synaptic plasticity. Among its several isoforms, NRG1-beta 2 has garnered significant interest due to its role in the modulation of neurotransmitter release and its potential implications in neurological disorders such as schizophrenia and Alzheimer's disease. Research has shown that NRG1-beta 2 interacts with the ErbB receptor family, influencing synaptic function and neurodevelopmental processes. Advances in recombinant protein technology have enabled the production of NRG1-beta 2 for in-depth functional studies and therapeutic applications. By generating and characterizing NRG1-beta 2 recombinant protein, researchers aim to elucidate its molecular mechanism of action, assess its impact on neuronal signaling pathways, and explore its potential as a biomarker or therapeutic target for various neuropsychiatric conditions. The ongoing research on NRG1-beta 2 not only enhances our understanding of neurobiological processes but also opens new avenues for targeted pharmacological interventions. As such, the investigation of NRG1-beta 2 serves as a promising frontier in neuroscience research, with implications for both basic science and clinical applications.
